Principal Investigator

Sharad A.
Ghamande
Awardee Organization

Augusta University
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Georgia CaRes

Augusta University has been home to Georgia's only NCI Community Oncology Research Program Minority/Underserved Community Site (NCORP M/U Community Site) since 2014. In partnership with DeKalb Medical Center, Morehouse School of Medicine, University Blood and Cancer Center in Athens, Phoebe Putney Medical Center in Albany, Augusta Oncology Associates in Augusta, and St. Dominic-Jackson Memorial Hospital in Jackson, Mississippi, the Georgia CaRes NCORP M/U Site has enrolled 408 patients to NCI clinical trials, 47% of which are African American and other minorities. The main goals of this application are to sustain and grow our NCORP Community Site, focusing on improving patient outcomes and reducing health disparities in M/U populations throughout the State of Georgia and beyond. Georgia has some of the nation's worst cancer disparities. The cancer experience for African Americans in Georgia varies widely from that of Caucasians and is especially evident in the disproportionate and astounding mortality rates from several common cancers (e.g., colorectal and breast cancers). Our original program was aptly named Georgia CaRes (Georgia Cancer Research) and represents our shared commitment to cancer research, including studies in cancer control, cancer prevention, and cancer care delivery, as well as clinical trials from NCI's National Clinical Trials Network (NCTN). The renewal of Georgia CaRes will allow us to continue to serve large regions of the state with high concentrations of minority and medically underserved populations. We will accomplish this through the following Specific Aims: 1) Georgia CaRes will facilitate participation and enrollment of patients and healthcare providers into cancer control, prevention, and cancer care delivery research (CCDR) studies developed by NCI's Research Bases and in human research trials of the National Clinical Trials Network (NCTN); 2) Georgia CaRes will support and strengthen NCORP goals by improving the scope of our activities as an NCORP M/U Community Site; and 3) Georgia CaRes will increase collaboration across our NCORP M/U Community network and with the Research Bases. Renewal of Georgia CaRes will have a significant and far-reaching impact on the health of minority and underserved populations within the State of Georgia and beyond.

Publications

  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
  • Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 May 15;24(10):2285-2293. Epub 2018 Mar 2. PMID: 29500276
  • Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast cancer research and treatment. 2017 Sep;165(2):375-382. Epub 2017 Jun 16. PMID: 28623430
  • Barton DL, Atherton PJ, Satele DV, Qin R, Dakhil S, Pipe T, Hobday T, Fee-Schroeder K, Loprinzi CL. A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Dec;28(12):6085-6094. Epub 2020 Apr 19. PMID: 32307658
  • Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 Jan 18. Epub 2024 Jan 18. PMID: 38236702